Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/1999
03/25/1999WO1999014340A1 Human prl-1 phosphatase
03/25/1999WO1999014334A1 Peptides derived from the attachment (g) protein of respiratory syncytial virus
03/25/1999WO1999014328A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/25/1999WO1999014237A1 Macrophage derived chemokine (mdc) as an anti-viral agent for the treatment and prevention of lentivirus infections
03/25/1999WO1999014233A1 Peptides derived from cowdria ruminantium, antibodies thereto and their diagnostical and medical uses
03/25/1999WO1999014231A2 Bifidus stimulating peptides and its uses
03/25/1999WO1999014226A2 Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
03/25/1999WO1999014218A1 Carbapenem derivatives and a preparation method thereof
03/25/1999WO1999014217A1 Aryloxymethyl carbapenem antibacterials
03/25/1999WO1999014215A1 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein
03/25/1999WO1999014214A1 Antimicrobial quinolones, their compositions and uses
03/25/1999WO1999014185A1 Compounds containing six-membered rings, processes for their preparation, and their use as medicaments
03/25/1999WO1999013915A1 Method of delivering genes to antigen presenting cells of the skin
03/25/1999WO1999013906A1 Multivalent vaccines
03/25/1999WO1999013896A1 Attenuated vif dna immunization cassettes for genetic vaccines
03/25/1999WO1999013894A2 Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
03/25/1999WO1999013893A1 Peptide nucleic acids having antibacterial activity
03/25/1999WO1999013888A1 Germicidal compositions for the treatment of animal infectious diseases of the hoof, comprising a copper salt, a quaternary ammonium compound and a peroxide
03/25/1999WO1999013872A1 Antimicrobials
03/25/1999WO1999013816A2 Liposomal camptothecin formulations
03/25/1999WO1999013720A1 Outer membrane protein of ehrlichia canis and ehrlichia chaffeensis
03/25/1999WO1998057994A3 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
03/25/1999WO1998056398A3 A method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
03/25/1999WO1998054225A3 Human-cd28 specific monoclonal antibodies for antigen non-specific activation of t-lymphocytes
03/25/1999WO1998051665A3 Novel macrocyclic compounds as metalloprotease inhibitors
03/25/1999DE19741051A1 New tetrahydroquinoline derivatives useful in treatment of raised lipid levels and arteriosclerosis
03/25/1999CA2382376A1 Novel polypeptides and nucleic acids encoding pro287 which are useful for treating disorders of the pancreas
03/25/1999CA2304982A1 Sense mrna therapy
03/25/1999CA2304267A1 Aryloxymethyl carbapenem antibacterials
03/25/1999CA2304256A1 Outer membrane protein of ehrlichia canis and ehrlichia chaffeensis
03/25/1999CA2304125A1 Attenuated vif dna immunization cassettes for genetic vaccines
03/25/1999CA2303834A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/25/1999CA2303397A1 Macrophage derived chemokine (mdc) as an anti-viral agent for the treatment and prevention of lentivirus infections
03/25/1999CA2303366A1 Liposomal camptothecin formulations
03/25/1999CA2303323A1 Compounds containing six-membered rings, processes for their preparation, and their use as medicaments
03/25/1999CA2303299A1 Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
03/25/1999CA2303227A1 Human prl-1 phosphatase
03/25/1999CA2303105A1 Multivalent vaccines
03/25/1999CA2302834A1 Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
03/25/1999CA2302316A1 Method of delivering genes to antigen presenting cells of the skin
03/25/1999CA2302251A1 Antimicrobial agent
03/25/1999CA2244978A1 Novel alcohol dehydrogenase
03/25/1999CA2244967A1 Murf
03/25/1999CA2244954A1 Murf
03/24/1999EP0903409A2 Aminopeptidase (AmpS)
03/24/1999EP0903408A2 Tat-derived transport polypeptide
03/24/1999EP0903407A2 Streptococcus pneumoniae phoH gene
03/24/1999EP0903406A1 Modulation of gene expression through interference with RNA secondary structure
03/24/1999EP0903345A1 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid
03/24/1999EP0903148A2 Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
03/24/1999EP0902832A1 Anol esters as bleach activators for detergents and cleaners
03/24/1999EP0902782A1 Urea derivatives as inhibitors of impdh enzyme
03/24/1999EP0902781A1 Preparation of (s)-decahydroisoquinoline-3-carboxylic acid t-butylamide
03/24/1999EP0902779A2 Phosphate mimics
03/24/1999EP0673199B1 Stabilized lanthionine bacteriocin compositions
03/24/1999EP0589995B1 Novel polypeptides and their use
03/24/1999CN1212055A Systems and method for quantifying photoreactions in light activated materials
03/24/1999CN1211985A Fused imidazole derivatives as multidrug resistance modulators
03/24/1999CN1211984A Possibly substituted 8-cyano-cyclopropyl-7-(2,8-diazabicyclo-[4,3,0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
03/24/1999CN1211924A Immunomodulatory complex for helicobacter bacteria
03/24/1999CN1211569A Substituted quinolone derivatives and pharmaceuticals containing the same
03/24/1999CN1211449A Neospora veccine
03/24/1999CN1211425A New drug for preventing and curing prawn disease and its manufacturing method
03/24/1999CN1211422A Prescription for treating hepatitis and tuberculosis
03/24/1999CN1211421A Medicament for preventing and curing several fish diseases
03/24/1999CN1042632C Pyridone carboxylic acid derivatives, intermediate and pharmaceutical composition for preparing same
03/23/1999US5886179 Nucleotide analogs
03/23/1999US5886175 Tetracycline antibiotics
03/23/1999US5886172 Oral prodrug readily absorped in the digestive tract and hydrolyzed; bioavailabiity; strong antibacterial activity especially against staphylococcus; streptococcus, klebsiella and proteus
03/23/1999US5886163 A recombinant nucleic acid molecule which encodes a mutant hiv-1 gp120 envelope glycoprotein comprising a v3 loop deletion and a c4 domains.sub.(w.fwdarw.x) point mutation, wherein x is an amino acid residue other than tryptophan
03/23/1999US5886039 Administering to uretha a lipophilic active agent selected from the group consisting of vasoactive prostaglandins
03/23/1999US5886036 Treating hiv infections
03/23/1999US5885996 An enzyme inhibitors of thymidylate synthase works as bactericides, fungicides inhibiting yeasts, fungi
03/23/1999US5885981 Reacting a halogenated alkyl compound with a penem compound
03/23/1999US5885972 L-pyranosyl nucleosides
03/23/1999US5885823 Bacteria strain atcc no.55783 are incubated in an oxygen concentration of from about 0 percent to about 18 percent, agitating the bacteria in suspension; veterinary medicine
03/23/1999US5885811 Leader sequence inducing a post-translational modification of polypeptides in bacteria gene therefor and subtilin variant of enhanced stability and activity
03/23/1999US5885805 gbpA
03/23/1999US5885804 Genetic engineered polynucleotides and encoded polypeptides of the atp-binding protein family, treating meningitis, infection of cerebrospinal fluid
03/23/1999US5885800 DNA encoding tumor necrosis related receptor, TR4
03/23/1999US5885768 Immunogenic peptides derived from the orf1, orf2, and orf3 regions of hepatitis e virus (hev), diagnostic reagents containing the peptide antigens, vaccine compositions containing the antigens, antibodies
03/23/1999US5885589 Pasteurella vaccine
03/23/1999US5885587 Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens
03/23/1999US5885586 Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
03/23/1999US5885585 Virus derived from 65th passage of cpv-39; vaccines against canine parvovirus or feline panleukopenia virus
03/23/1999US5885580 A fusion protein obtained by inserting a foreign antigen peptide into the molecular surface of an antigen derived from mycobacteria, has significant increased antigenicity and immunogenicity
03/23/1999US5885578 Immunizing a mammal with immunogen comprising two or more hiv proteins, free of outer envelope protein, which stimulates production of anti-hiv antibodies and recovering the produced anti-hiv antibodies
03/23/1999US5885576 Vaccines and methods for preventing and treating fescue toxicosis in herbivores
03/23/1999US5885572 Administering polypeptide or active fragment to treat bacterial infections
03/23/1999CA2002597C Solvates of b-lactam antibiotic
03/22/1999CA2244239A1 Novel era
03/18/1999WO1999013097A1 Stabilization of helicobacter urease
03/18/1999WO1999013095A2 Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
03/18/1999WO1999013092A1 Enhancement of mucosal antibody responses by interleukin-6
03/18/1999WO1999013084A1 Group a streptococcal vaccines
03/18/1999WO1999013080A1 Beta-defensins
03/18/1999WO1999013055A1 Human sigma receptor
03/18/1999WO1999012971A2 Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile toxins
03/18/1999WO1999012968A2 Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response
03/18/1999WO1999012951A1 Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
1 ... 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 ... 1798